Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study
dc.rights.license | open | en_US |
dc.contributor.author | KERBER, R. | |
dc.contributor.author | LORENZ, E. | |
dc.contributor.author | DURAFFOUR, S. | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | SISSOKO, Daouda | |
dc.contributor.author | RUDOLF, M. | |
dc.contributor.author | JAEGER, A. | |
dc.contributor.author | CISSE, S. D. | |
dc.contributor.author | CAMARA, A. M. | |
dc.contributor.author | MIRANDA, O. | |
dc.contributor.author | CASTRO, C. M. | |
dc.contributor.author | AKOI BORE, J. | |
dc.contributor.author | RAYMOND KOUNDOUNO, F. | |
dc.contributor.author | REPITS, J. | |
dc.contributor.author | AFROUGH, B. | |
dc.contributor.author | BECKER-ZIAJA, B. | |
dc.contributor.author | HINZMANN, J. | |
dc.contributor.author | MERTENS, M. | |
dc.contributor.author | VITORIANO, I. | |
dc.contributor.author | HUGH LOGUE, C. | |
dc.contributor.author | BOTTCHER, J. P. | |
dc.contributor.author | PALLASCH, E. | |
dc.contributor.author | SACHSE, A. | |
dc.contributor.author | BAH, A. | |
dc.contributor.author | CABEZA-CABRERIZO, M. | |
dc.contributor.author | NITZSCHE, K. | |
dc.contributor.author | KUISMA, E. | |
dc.contributor.author | MICHEL, J. | |
dc.contributor.author | HOLM, T. | |
dc.contributor.author | ZEKENG, E. G. | |
dc.contributor.author | COWLEY, L. A. | |
dc.contributor.author | GARCIA-DORIVAL, I. | |
dc.contributor.author | HETZELT, N. | |
dc.contributor.author | BAUM, J. H. J. | |
dc.contributor.author | PORTMANN, J. | |
dc.contributor.author | CARTER, L. | |
dc.contributor.author | YENAMABERHAN, R. L. | |
dc.contributor.author | CAMINO, A. | |
dc.contributor.author | ENKIRCH, T. | |
dc.contributor.author | SINGETHAN, K. | |
dc.contributor.author | MEISEL, S. | |
dc.contributor.author | MAZZARELLI, A. | |
dc.contributor.author | KOSGEI, A. | |
dc.contributor.author | KAFETZOPOULOU, L. | |
dc.contributor.author | RICKETT, N. Y. | |
dc.contributor.author | PATRONO, L. V. | |
dc.contributor.author | GHEBREGHIORGHIS, L. | |
dc.contributor.author | ARNOLD, U. | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | COLIN, Geraldine | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | JUCHET, Sylvain | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | LEVY-MARCHAL, Claire | |
dc.contributor.author | KOLIE, J. S. | |
dc.contributor.author | BEAVOGUI, A. H. | |
dc.contributor.author | WURR, S. | |
dc.contributor.author | BOCKHOLT, S. | |
dc.contributor.author | KRUMKAMP, R. | |
dc.contributor.author | MAY, J. | |
dc.contributor.author | STOECKER, K. | |
dc.contributor.author | FLEISCHMANN, E. | |
dc.contributor.author | IPPOLITO, G. | |
dc.contributor.author | CARROLL, M. W. | |
dc.contributor.author | KOIVOGUI, L. | |
dc.contributor.author | MAGASSOUBA, N. | |
dc.contributor.author | KEITA, S. | |
dc.contributor.author | GURRY, C. | |
dc.contributor.author | DRURY, P. | |
dc.contributor.author | DIALLO, B. | |
dc.contributor.author | FORMENTY, P. | |
dc.contributor.author | WOLFEL, R. | |
dc.contributor.author | CARO, A. D. | |
dc.contributor.author | GABRIEL, M. | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | ANGLARET, Xavier | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | MALVY, Denis | |
dc.contributor.author | GUNTHER, S. | |
dc.date.accessioned | 2020-06-25T08:50:25Z | |
dc.date.available | 2020-06-25T08:50:25Z | |
dc.date.issued | 2019-06-19 | |
dc.identifier.issn | 1537-6613 (Electronic) 0022-1899 (Linking) | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/8187 | |
dc.description.abstractEn | BACKGROUND: In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. Cycle threshold (Ct) in the Ebola virus RT-PCR and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to EVD patients on compassionate use basis. METHODS: To reduce biases in the raw field data, we carefully selected 163 of the 286 EVD patients for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry, favipiravir treatment, and outcome. RESULTS: The case fatality rate in favipiravir-treated patients was lower than in untreated patients (31/73 [42.5%] vs. 52/90 [57.8%], p = 0.053 in univariate analysis). In the multivariate regression analysis, higher Ct value and younger age were associated with survival (p <0.001), while favipiravir treatment showed no statistically significant effect (p = 0.11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (p = 0.015). The study also showed characteristic changes in blood chemistry in fatal cases vs. survivors. CONCLUSIONS: Consistent with the JIKI trial, this retrospective study reveals a trend toward improved survival in favipiravir-treated patients; however, the effect was not statistically significant except for survival time. | |
dc.language.iso | EN | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.en | IDLIC | |
dc.title.en | Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study | |
dc.title.alternative | J Infect Dis | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1093/infdis/jiz078 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 30788508 | en_US |
bordeaux.journal | Journal of Infectious Diseases | en_US |
bordeaux.page | 195-202 | en_US |
bordeaux.volume | 220 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 2 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03209953 | |
hal.version | 1 | |
hal.date.transferred | 2021-04-27T13:41:50Z | |
hal.export | true | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Infectious%20Diseases&rft.date=2019-06-19&rft.volume=220&rft.issue=2&rft.spage=195-202&rft.epage=195-202&rft.eissn=1537-6613%20(Electronic)%200022-1899%20(Linking)&rft.issn=1537-6613%20(Electronic)%200022-1899%20(Linking)&rft.au=KERBER,%20R.&LORENZ,%20E.&DURAFFOUR,%20S.&SISSOKO,%20Daouda&RUDOLF,%20M.&rft.genre=article |